VRAX — Virax Biolabs Group Ltd
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1885827 ·
Last close
$0.23
Market Cap
$1.69M
52W High
$0.53
52W Low
$0.10
ADV30
37,616,001
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | — | — | — | — | 5,715,015 | 3,345,464 | 641,516 |
| Mar 2025 | — | — | — | — | 6,426,903 | 4,228,944 | 964,750 |
| Sep 2024 | — | — | — | — | 9,442,944 | 7,285,991 | 1,026,067 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-26,928,015
Inventory
$54,186
Receivables
$175,697
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,986
EBITDA
$-5,556,497
Free Cash Flow
$-3,539,977
Enterprise Value
$-1,322,521
Total Cash
$3,437,848
Total Debt
$537,993
Shares Out
7,423,432
Trailing EPS
$-1.22
Book Value
$0.81
ROE
-83.8%
ROA
-48.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 6,331 | -6,162,897 | -6,061,247 | 6,426,903 | 964,750 | — | -4,563,576 |
| Mar 2024 | 156,419 | -6,106,118 | -6,733,537 | 5,483,969 | 345,194 | — | -6,247,016 |
| Mar 2023 | 8,561 | -5,732,761 | -5,457,494 | 9,812,416 | 908,401 | — | -4,179,767 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BZYR | BURZYNSKI RESEARCH INSTITUTE INC | $1.45M | $0.01 | — |
| CBIH | Cannabis Bioscience International Holdings, Inc. | $3.49M | $0.00 | — |
| ISPC | iSpecimen Inc. | $4.86M | $3.38 | — |
| BUDZ | WEED, INC. | $5.04M | $0.03 | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5.24M | $1.77 | — |
News headlines (Yahoo Finance, 1h cache)
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
2026-05-26 11:30 · Yahoo
Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-05-15 13:00 · Yahoo
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
2026-04-14 11:34 · Yahoo
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
2026-01-15 17:00 · Yahoo
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
2025-12-04 21:05 · Yahoo
Virax Biolabs Group Limited Announces $5 Million Private Placement
2025-12-03 18:53 · Yahoo
BC-Most Active Stocks
2025-12-03 15:30 · Yahoo
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
2025-12-03 12:34 · Yahoo
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
2025-11-03 13:29 · Yahoo
Virax Biolabs (VRAX) Falls 18% on Lack of Leads
2025-08-27 16:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.